Pathognomonic Cell of B Cell PLL Quiz

The pathognomonic cell of B cell PLL is a __________

The diffuse proliferation of small lymphoid cells with prolymphocyte of medium size with round nucleus, pseudofollicles is pathognomonic for __________.

PLL is positive for pan–B cell markers CD20, monoclonal B lymphocytes with CLL CD19, CD22, and __________.

The density of CD20 and surface light chain is higher than in typical cases of CLL/SLL, with a count greater than __________/uL.

Morphologic features of T cell PLL are not as distinct as those of the B cell type. Neoplastic cells seen in peripheral blood films are small to medium size, with round or irregular nuclei, the latter resembling __________ cells.

Immunophenotyping also demonstrates expression of kappa or lambda light chains (clonal light chain of cases. Cytoplasmic blebbing is __________.

Next generation sequencing has recently identified additional significant genetic mutations such as EZH2, NOTCH1, SF3B1, and BIRC3, which can be used for an assessment of prognosis in ____________.

Smudge cells, representing disintegrated lymphoid cells, are typically seen on peripheral blood films of ____________ patients.

Prolymphocytic leukemia (PLL) is a rare mature specimen derived from ____________ cells.

Lymph nodes involved by SLL show an effacement of normal nodal architecture by a diffuse proliferation of cell PLL small, round lymphoid cells with coarse chromatin, indistinct nucleoli, and scant cytoplasm. SLL stands for ____________.

This lymphoproliferative disease is distinct from CLL and its diagnosis requires that more than 55% of ____________ cells are observed.

In addition, scattered nodules composed of medium-sized and large lymphoid cells with dispersed chromatin and distinct nucleoli are observed in ____________.

Bone marrow, spleen, lymph node, and occasionally skin involvement is diffuse, with accentuation in nodal expression and the absence of FMC7, cyclin D1, and paracortical areas and around the vessels in dermis. SOX11 distinguish CLL/SLL from mantle cell - A combination of morphologic, clinical, and lymphoma.immunophenotypic features is most helpful in making - The presence of less than 5000/mL of circulating the diagnosis. monoclonal B cells with a CLL/SLL immunophenotype. PLL stands for B cell __________.

T prolymphocytes are positive for T cell markers such as CD3, CD2, and CD5. Most commonly CD4 antigen is expressed. A minority of cases can be double positive for CD4 and CD8, or positive for CD8. CLL/SLL can be distinguished by the expression of SOX11 in the absence of cyclin D1. SOX11 is helpful to differentiate CLL/SLL from mantle cell lymphoma and __________.

CLINICAL FEATURES AND PROGNOSIS - Like CLL/SLL, PLL is a disease of the elderly (mean age of presentation is 70 years). A combination of morphologic, clinical, and lymphoma immunophenotypic features is most helpful in making the diagnosis. PLL is characterized by the presence of less than 5000/mL of circulating monoclonal B cells with a CLL/SLL immunophenotype. PLL is a B cell __________.

PLL is characterized by the presence of less than 5000/mL of circulating monoclonal B cells with a CLL/SLL immunophenotype. SOX11 is used to differentiate CLL/SLL from mantle cell lymphoma and PLL. The absence of FMC7, cyclin D1, and paracortical areas and around the vessels in dermis help in the diagnosis of PLL. CD23 and LEF1 are also markers used in the diagnosis of PLL, with the former being negative. The morphologic features of T cell PLL include the presence of T prolymphocytes that are positive for T cell markers such as CD3, CD2, and CD5. In T cell PLL, a minority of cases can be double positive for CD4 and CD8, or positive for CD8. PLL stands for B cell prolymphocytic __________.

Like CLL/SLL, PLL is a disease of the elderly (mean age of presentation is 70 years). SOX11 is a marker used to differentiate CLL/SLL from mantle cell lymphoma and PLL. In PLL, a combination of morphologic, clinical, and lymphoma immunophenotypic features is most helpful in making the diagnosis. The presence of less than 5000/mL of circulating monoclonal B cells with a CLL/SLL immunophenotype is a key characteristic of PLL. PLL is a B cell lymphoproliferative __________.